A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.
R0
nal-irinotecan
peri-operative chemotherapy
resectable pancreatic adenocarcinoma
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
03
2020
accepted:
13
07
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
7
1
2021
Statut:
epublish
Résumé
Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance status. liposomal irinotecan (Nal-IRI) is a novel nanoliposome formulation of irinotecan that accumulates in tumor-associated macrophages improving the therapeutic index of irinotecan and has been approved for the treatment of patients with metastatic pancreatic cancer after progression under gemcitabine-based therapy. Thus, it remains of the outmost urgency to investigate introduction of the most novel agents, such as nal-IRI, in perioperative approaches aimed at increasing the long-term effectiveness of surgery. The nITRO trial is a phase II, single-arm, open-label study to assess the safety and the activity of nal-IRI with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin in the perioperative treatment of patients with resectable pancreatic cancer. The primary tumor must be resectable with no involvement of the major arteries and no involvement or <180° interface between tumor and vessel wall of the major veins. A total of 72 patients will be enrolled to receive a perioperative treatment of three cycles before and three cycles after surgical resection with nal-IRI 50 mg/m The nITRO trial will contribute to strengthen the clinical evidence supporting perioperative strategies in resectable pancreatic cancer patients. Moreover, this study represents a unique opportunity for translational analyses aimed to identify novel immune-related prognostic and predictive factors in this setting. Clinicaltrial.gov: NCT03528785. Trial registration data: 1 January 2018Protocol number: CRC 2017_01EudraCT Number: 2017-000345-46.
Sections du résumé
BACKGROUND
BACKGROUND
Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance status. liposomal irinotecan (Nal-IRI) is a novel nanoliposome formulation of irinotecan that accumulates in tumor-associated macrophages improving the therapeutic index of irinotecan and has been approved for the treatment of patients with metastatic pancreatic cancer after progression under gemcitabine-based therapy. Thus, it remains of the outmost urgency to investigate introduction of the most novel agents, such as nal-IRI, in perioperative approaches aimed at increasing the long-term effectiveness of surgery.
METHODS
METHODS
The nITRO trial is a phase II, single-arm, open-label study to assess the safety and the activity of nal-IRI with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin in the perioperative treatment of patients with resectable pancreatic cancer. The primary tumor must be resectable with no involvement of the major arteries and no involvement or <180° interface between tumor and vessel wall of the major veins. A total of 72 patients will be enrolled to receive a perioperative treatment of three cycles before and three cycles after surgical resection with nal-IRI 50 mg/m
DISCUSSION
CONCLUSIONS
The nITRO trial will contribute to strengthen the clinical evidence supporting perioperative strategies in resectable pancreatic cancer patients. Moreover, this study represents a unique opportunity for translational analyses aimed to identify novel immune-related prognostic and predictive factors in this setting.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrial.gov: NCT03528785. Trial registration data: 1 January 2018Protocol number: CRC 2017_01EudraCT Number: 2017-000345-46.
Identifiants
pubmed: 33403007
doi: 10.1177/1758835920947969
pii: 10.1177_1758835920947969
pmc: PMC7745557
doi:
Banques de données
ClinicalTrials.gov
['NCT03528785']
Types de publication
Journal Article
Langues
eng
Pagination
1758835920947969Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest: DM declares research funding from Shire, Incyte, Evotec, Celgene, iOnctura and consulting role with Eli Lilly, Shire, Evotec, Baxter, Incyte, iOnctura.
Références
Ann Surg. 2001 Dec;234(6):758-68
pubmed: 11729382
J Clin Oncol. 2017 Feb 10;35(5):515-522
pubmed: 27621388
Cancer Res. 2006 Mar 15;66(6):3271-7
pubmed: 16540680
Oncoimmunology. 2017 Apr 28;6(9):e1322242
pubmed: 28932629
Br J Surg. 2018 Jul;105(8):946-958
pubmed: 29708592
Lancet. 2004 Mar 27;363(9414):1049-57
pubmed: 15051286
Surg Oncol Clin N Am. 2016 Apr;25(2):311-26
pubmed: 27013366
Cancer Res. 2014 Dec 1;74(23):7003-13
pubmed: 25273092
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Ann Surg. 2006 Jul;244(1):10-5
pubmed: 16794383
Histopathology. 2009 Sep;55(3):277-83
pubmed: 19723142
Dig Liver Dis. 2018 Dec;50(12):1257-1271
pubmed: 30219670
J Am Coll Surg. 2007 Mar;204(3):347-55
pubmed: 17324767
Cancer Chemother Pharmacol. 2019 May;83(5):975-991
pubmed: 30887178
Br J Surg. 2004 May;91(5):586-94
pubmed: 15122610
Front Pharmacol. 2013 Apr 30;4:56
pubmed: 23641216
J Gastrointest Oncol. 2011 Sep;2(3):185-94
pubmed: 22811849
Transl Gastroenterol Hepatol. 2019 Mar 27;4:21
pubmed: 30976724
Ann Surg. 2010 Jun;251(6):1003-10
pubmed: 20485150
World J Surg. 2003 Mar;27(3):324-9
pubmed: 12607060
Anticancer Res. 2018 Aug;38(8):4889-4895
pubmed: 30061265
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
JAMA. 2010 Sep 8;304(10):1073-81
pubmed: 20823433
Br J Cancer. 2017 May 9;116(10):1247-1253
pubmed: 28350787
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Crit Rev Oncol Hematol. 2017 Jul;115:1-12
pubmed: 28602164
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
World J Gastroenterol. 2015 Apr 28;21(16):4788-801
pubmed: 25944992
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
Ann Surg. 2007 Jul;246(1):52-60
pubmed: 17592291
Ann Surg Oncol. 2008 Oct;15(10):2773-86
pubmed: 18612703
Expert Opin Ther Targets. 2011 Oct;15(10):1183-96
pubmed: 21819318
Eur J Cancer. 2019 Jan;106:24-33
pubmed: 30458340
Cell. 2012 Jan 20;148(1-2):362-75
pubmed: 22265421
Curr Pharm Des. 2014;20(42):6660-9
pubmed: 25341938
ESMO Open. 2020 Jan;5(1):
pubmed: 31958291
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Ann Surg. 1993 Feb;217(2):144-8
pubmed: 8094952
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Br J Surg. 2006 Oct;93(10):1232-7
pubmed: 16804874
Surg Clin North Am. 2018 Feb;98(1):95-111
pubmed: 29191281
J Am Coll Surg. 2012 Jan;214(1):33-45
pubmed: 22055585
J Natl Cancer Inst. 2019 Aug 1;111(8):782-794
pubmed: 31086963
World J Surg Oncol. 2017 Oct 10;15(1):183
pubmed: 29017581
Clin Cancer Res. 2015 Mar 1;21(5):1139-50
pubmed: 25733708
J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion 24-5
pubmed: 24241967
Surgery. 2011 Oct;150(4):607-16
pubmed: 22000171
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60
pubmed: 9339931
Langenbecks Arch Surg. 2010 Apr;395(4):451-8
pubmed: 19418067
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423
pubmed: 29625841
J Surg Oncol. 2018 Mar;117(3):354-362
pubmed: 29044544
Ann Surg Oncol. 2008 Jun;15(6):1651-60
pubmed: 18351300
Ann Gastroenterol Surg. 2020 Feb 12;4(3):216-223
pubmed: 32490335
Br J Cancer. 2018 Nov;119(10):1208-1214
pubmed: 30318515
Cells. 2020 Jan 28;9(2):
pubmed: 32012917